JP2015509972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509972A5 JP2015509972A5 JP2014561514A JP2014561514A JP2015509972A5 JP 2015509972 A5 JP2015509972 A5 JP 2015509972A5 JP 2014561514 A JP2014561514 A JP 2014561514A JP 2014561514 A JP2014561514 A JP 2014561514A JP 2015509972 A5 JP2015509972 A5 JP 2015509972A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- metal salt
- lactose
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610012P | 2012-03-13 | 2012-03-13 | |
| US201261610023P | 2012-03-13 | 2012-03-13 | |
| US61/610,023 | 2012-03-13 | ||
| US61/610,012 | 2012-03-13 | ||
| PCT/GB2013/050623 WO2013136075A1 (en) | 2012-03-13 | 2013-03-13 | Novel pharmaceutical formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509972A JP2015509972A (ja) | 2015-04-02 |
| JP2015509972A5 true JP2015509972A5 (enExample) | 2016-04-14 |
| JP6189874B2 JP6189874B2 (ja) | 2017-08-30 |
Family
ID=49160309
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561514A Expired - Fee Related JP6189874B2 (ja) | 2012-03-13 | 2013-03-13 | 新規製薬学的製剤 |
| JP2014561515A Pending JP2015509973A (ja) | 2012-03-13 | 2013-03-13 | 結晶性ｐｉ３キナーゼ阻害剤 |
| JP2017151378A Withdrawn JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性ｐｉ３キナーゼ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561515A Pending JP2015509973A (ja) | 2012-03-13 | 2013-03-13 | 結晶性ｐｉ３キナーゼ阻害剤 |
| JP2017151378A Withdrawn JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性ｐｉ３キナーゼ阻害剤 |
Country Status (35)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| SI2834244T1 (sl) | 2012-03-13 | 2016-12-30 | Respivert Limited | Inhibitorji kristalinične PI3 kinaze |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
| AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| MX389256B (es) | 2013-10-04 | 2025-03-20 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| PE20170640A1 (es) | 2014-07-04 | 2017-05-26 | Lupin Ltd | Derivados de quinolizinona como inhibidores de pi3k |
| US20180021256A1 (en) | 2014-07-09 | 2018-01-25 | Arven Ilac Sanayi Ve Ticaret A.S. | Process for the preparation of formulations for inhalation |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| AU2017251548B2 (en) * | 2016-04-15 | 2022-02-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Inhaled preparation of isoglycyrrhizic acid or salt thereof and use in preparing drugs for treating respiratory system diseases |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| WO1999028979A2 (en) | 1997-12-02 | 1999-06-10 | Alcatel Usa Sourcing, L.P. | Digital phone system |
| CA2347856C (en) | 1998-11-13 | 2009-02-17 | Jagotec Ag | Dry powder for inhalation |
| AU779008C (en) | 1999-01-11 | 2005-06-30 | Princeton University | High affinity inhibitors for target validation and uses thereof |
| PL196951B1 (pl) | 1999-03-05 | 2008-02-29 | Chiesi Farma Spa | Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| CN100345830C (zh) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| JP2005509594A (ja) | 2001-07-13 | 2005-04-14 | バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド | Ｎａｄシンテターゼ阻害剤およびその使用 |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
| CA2520121A1 (en) | 2003-04-03 | 2004-10-21 | Protein Design Labs, Inc. | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| GB0316341D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
| JP2009513529A (ja) * | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
| US20100267778A1 (en) | 2003-08-04 | 2010-10-21 | Shinya Kusuda | Diphenyl ether compound, process for producing the same, and use |
| WO2005016349A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Methods of inhibiting leukocyte accumulation |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| PL1761540T3 (pl) | 2004-05-13 | 2017-06-30 | Icos Corporation | Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta |
| JP2008500338A (ja) | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び／又は予防する方法 |
| EP1750715A1 (en) | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
| KR101231466B1 (ko) | 2004-09-13 | 2013-02-07 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제 |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| EP1885356A2 (en) | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| CN101506211B (zh) | 2006-04-04 | 2013-05-22 | 加利福尼亚大学董事会 | 激酶拮抗剂 |
| KR101499783B1 (ko) | 2006-04-04 | 2015-03-09 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| MX2008014910A (es) | 2006-05-24 | 2009-01-23 | Bayer Schering Pharma Ag | Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida. |
| KR20090031544A (ko) | 2006-06-29 | 2009-03-26 | 쉐링 코포레이션 | 치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제 |
| GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2008058402A1 (en) | 2006-11-17 | 2008-05-22 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| KR20100019489A (ko) | 2007-05-09 | 2010-02-18 | 노파르티스 아게 | Ｐｉ３ｋ 지질 키나제 억제제로서의 치환된 이미다조피리다진 |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| US20110269779A1 (en) | 2008-11-18 | 2011-11-03 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| US20110294803A1 (en) | 2008-12-04 | 2011-12-01 | Law Amanda J | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
| EP2379505A4 (en) | 2008-12-05 | 2012-10-17 | Designmedix Inc | CHLOROQUINES MODIFIED BY A MONOCYCLIC GROUP OR A FUSED CYCLE GROUP |
| US20110135655A1 (en) | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
| SG174529A1 (en) | 2009-03-24 | 2011-10-28 | Gilead Calistoga Llc | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| IN2012DN01254A (enExample) | 2009-08-05 | 2015-05-15 | Versitech Ltd | |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| WO2011083387A1 (en) * | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| CN201676365U (zh) | 2010-03-29 | 2010-12-22 | 山东京卫制药有限公司 | 带有语音提示的给药吸入装置 |
| CN201692450U (zh) | 2010-06-22 | 2011-01-05 | 于清 | 用于药物输送的高效干粉吸入器 |
| AU2011298315B2 (en) * | 2010-08-31 | 2014-08-28 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| EP2621494B1 (en) | 2010-09-30 | 2018-11-07 | Chiesi Farmaceutici S.p.A. | Use of magnesium stearate in dry powder formulations for inhalation |
| UY33337A (es) * | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| CN202154919U (zh) | 2011-05-03 | 2012-03-07 | 王晓明 | 一种防交叉感染雾化吸入装置 |
| SI2834244T1 (sl) | 2012-03-13 | 2016-12-30 | Respivert Limited | Inhibitorji kristalinične PI3 kinaze |
-
2013
- 2013-03-13 SI SI201330362A patent/SI2834244T1/sl unknown
- 2013-03-13 TW TW102108766A patent/TWI586378B/zh not_active IP Right Cessation
- 2013-03-13 MX MX2014010991A patent/MX355299B/es active IP Right Grant
- 2013-03-13 US US14/381,289 patent/US9642799B2/en not_active Expired - Fee Related
- 2013-03-13 TW TW102108767A patent/TWI617561B/zh not_active IP Right Cessation
- 2013-03-13 CN CN201380013851.3A patent/CN104302650B/zh not_active Expired - Fee Related
- 2013-03-13 SG SG11201404522VA patent/SG11201404522VA/en unknown
- 2013-03-13 HR HRP20161383TT patent/HRP20161383T1/hr unknown
- 2013-03-13 KR KR1020147026305A patent/KR20140131971A/ko not_active Ceased
- 2013-03-13 KR KR1020147026258A patent/KR20140141596A/ko not_active Ceased
- 2013-03-13 CA CA 2864652 patent/CA2864652A1/en not_active Abandoned
- 2013-03-13 IN IN1998MUN2014 patent/IN2014MN01998A/en unknown
- 2013-03-13 MY MYPI2014702576A patent/MY171125A/en unknown
- 2013-03-13 EA EA201491674A patent/EA025465B1/ru not_active IP Right Cessation
- 2013-03-13 SG SG11201404519UA patent/SG11201404519UA/en unknown
- 2013-03-13 AU AU2013234080A patent/AU2013234080B2/en not_active Ceased
- 2013-03-13 UA UAA201408662A patent/UA115544C2/uk unknown
- 2013-03-13 NZ NZ628072A patent/NZ628072A/en not_active IP Right Cessation
- 2013-03-13 ES ES13711104.3T patent/ES2650791T3/es active Active
- 2013-03-13 JP JP2014561514A patent/JP6189874B2/ja not_active Expired - Fee Related
- 2013-03-13 NZ NZ627963A patent/NZ627963A/en not_active IP Right Cessation
- 2013-03-13 EA EA201491675A patent/EA023715B1/ru not_active IP Right Cessation
- 2013-03-13 JP JP2014561515A patent/JP2015509973A/ja active Pending
- 2013-03-13 EP EP13711105.0A patent/EP2834244B1/en active Active
- 2013-03-13 US US14/381,273 patent/US20150099768A1/en not_active Abandoned
- 2013-03-13 HU HUE13711105A patent/HUE029420T2/en unknown
- 2013-03-13 IN IN2000MUN2014 patent/IN2014MN02000A/en unknown
- 2013-03-13 MX MX2014010990A patent/MX357170B/es active IP Right Grant
- 2013-03-13 LT LTEP13711105.0T patent/LT2834244T/lt unknown
- 2013-03-13 ES ES13711105.0T patent/ES2600705T3/es active Active
- 2013-03-13 WO PCT/GB2013/050623 patent/WO2013136075A1/en not_active Ceased
- 2013-03-13 AU AU2013234081A patent/AU2013234081B2/en not_active Ceased
- 2013-03-13 CN CN201380013848.1A patent/CN104284679B/zh not_active Expired - Fee Related
- 2013-03-13 PE PE2014001415A patent/PE20142342A1/es not_active Application Discontinuation
- 2013-03-13 CA CA 2864643 patent/CA2864643A1/en not_active Abandoned
- 2013-03-13 EP EP13711104.3A patent/EP2825202B1/en active Active
- 2013-03-13 PE PE2014001414A patent/PE20141964A1/es not_active Application Discontinuation
- 2013-03-13 PT PT137111050T patent/PT2834244T/pt unknown
- 2013-03-13 PL PL13711105T patent/PL2834244T3/pl unknown
- 2013-03-13 DK DK13711105.0T patent/DK2834244T3/en active
- 2013-03-13 WO PCT/GB2013/050624 patent/WO2013136076A1/en not_active Ceased
-
2014
- 2014-07-30 IL IL233883A patent/IL233883A0/en unknown
- 2014-07-30 IL IL233886A patent/IL233886A/en not_active IP Right Cessation
- 2014-07-30 PH PH12014501713A patent/PH12014501713A1/en unknown
- 2014-08-27 PH PH12014501922A patent/PH12014501922A1/en unknown
- 2014-08-29 CO CO14190111A patent/CO7051030A2/es unknown
- 2014-08-29 CO CO14190112A patent/CO7061079A2/es unknown
- 2014-09-01 GT GT201400182A patent/GT201400182A/es unknown
- 2014-09-02 GT GT201400183A patent/GT201400183A/es unknown
- 2014-09-05 NI NI201400101A patent/NI201400101A/es unknown
- 2014-09-05 NI NI201400100A patent/NI201400100A/es unknown
- 2014-09-09 CL CL2014002385A patent/CL2014002385A1/es unknown
- 2014-09-09 CL CL2014002386A patent/CL2014002386A1/es unknown
- 2014-09-10 EC ECIEPI201418142A patent/ECSP14018142A/es unknown
- 2014-09-10 CR CR20140417A patent/CR20140417A/es unknown
- 2014-09-10 CR CR20140416A patent/CR20140416A/es unknown
- 2014-09-12 EC ECIEPI201418630A patent/ECSP14018630A/es unknown
- 2014-10-10 ZA ZA2014/07374A patent/ZA201407374B/en unknown
- 2014-10-10 ZA ZA2014/07373A patent/ZA201407373B/en unknown
-
2016
- 2016-11-09 CY CY20161101148T patent/CY1118565T1/el unknown
-
2017
- 2017-05-08 US US15/588,845 patent/US20170239256A1/en not_active Abandoned
- 2017-08-04 JP JP2017151378A patent/JP2018008992A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509972A5 (enExample) | ||
| JP2015509973A5 (enExample) | ||
| NZ627963A (en) | Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase | |
| HRP20210928T1 (hr) | Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| AU2020203497B2 (en) | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide | |
| JP2018534348A5 (enExample) | ||
| JP2012041365A5 (enExample) | ||
| JP2013541595A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2014532638A5 (enExample) | ||
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| RU2016123828A (ru) | Комбинированная композиция для перорального введения, содержащая эзетимиб и розувастатин | |
| CA2687741A1 (en) | Stabilized amorphous forms of imatinib mesylate | |
| CZ2016276A3 (cs) | Pevné formy volné báze ibrutinibu | |
| JP2009040767A5 (enExample) | ||
| JP2017507980A5 (enExample) | ||
| RU2016106336A (ru) | Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения | |
| NO20070952L (no) | Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike | |
| JP2020500168A5 (enExample) | ||
| JP2011500819A5 (enExample) | ||
| JP2020510061A5 (enExample) | ||
| JP2013526579A5 (enExample) | ||
| JP2016508995A5 (enExample) | ||
| JP2018528238A5 (enExample) | ||
| MY144613A (en) | Formulations of suberoylanilide hydroxamic acid and methods for producing same |